MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia
F. Brown, E. Still, P. Cifani, S. Takao, C. Reed, S. Ficarro, R. Koche, P. Romanienko, W. Mark, C. O'Donnell, B. Spitzer, C. Stutzke, A. Krivtsov, G. Pouliot, J. Marto, , A. Kentsis
This study identifies MEF2C phosphorylation as a marker of chemotherapy resistance in AML and shows that inhibiting this phosphorylation can overcome resistance in MEF2C-activated cells.
bioRxiv · Feb 9, 2017Cancer Biology